secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0000950170-25-101974
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax Q2 Revuforj revenue $28.6M (+43% QoQ); sNDA for mNPM1 AML with Priority Review
--------------------------------------------------------------------------------

- Revuforj net revenue $28.6M in Q2 2025, 43% increase over Q1 2025.
- Niktimvo net revenue $36.2M (Incyte-reported); Syndax collaboration revenue $9.4M.
- sNDA for Revuforj in R/R mNPM1 AML granted Priority Review; PDUFA Oct 25, 2025.
- Cash, cash equivalents and investments $517.9M; expect funding to profitability.
- Net loss $71.8M ($0.83/sh) vs $68.1M ($0.80/sh) year ago.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/0000950170-25-101974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-20250804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-101974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer